These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35109713)

  • 21. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrase inhibitor-based regimens are related to favorable systemic inflammatory index and platecrit scores in people living with HIV (PLWH) up to 2 years.
    Şahin EA; Mavi D; Kara E; Sönmezer MÇ; İnkaya AÇ; Ünal S
    Postgrad Med; 2022 Aug; 134(6):635-640. PubMed ID: 35671079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brief Report: Undercarboxylated Osteocalcin Is Associated With Cognition in Women With and Without HIV.
    Ross RD; Olali AZ; Shi Q; Hoover DR; Sharma A; Weber KM; French AL; McKay H; Tien PC; Yin MT; Rubin LH
    J Acquir Immune Defic Syndr; 2022 Oct; 91(2):162-167. PubMed ID: 36094482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France.
    Pugliese P; Joly V; Valantin MA; Cotte L; Huleux T; Allavena C; Reynes J; Poizot-Martin I; Bani-Sadr F; Cuzin L;
    Med Mal Infect; 2019 Jun; 49(4):264-269. PubMed ID: 30409541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.
    Brown TT; Li X; Cole SR; Kingsley LA; Palella FJ; Riddler SA; Chmiel JS; Visscher BR; Margolick JB; Dobs AS
    AIDS; 2005 Sep; 19(13):1375-83. PubMed ID: 16103768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
    Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
    Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China.
    Gao L; Xia H; Zeng R; Wu Y; Zaongo SD; Hu Y; Ma P
    HIV Med; 2022 Mar; 23 Suppl 1():84-94. PubMed ID: 35293099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
    Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
    BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incident Non-AIDS Comorbidity Burden Among Women With or at Risk for Human Immunodeficiency Virus in the United States.
    Collins LF; Sheth AN; Mehta CC; Naggie S; Golub ET; Anastos K; French AL; Kassaye S; Taylor TN; Fischl MA; Adimora AA; Kempf MC; Palella FJ; Tien PC; Ofotokun I
    Clin Infect Dis; 2021 Oct; 73(7):e2059-e2069. PubMed ID: 33388773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
    Duvivier C; Ghosn J; Assoumou L; Soulié C; Peytavin G; Calvez V; Génin MA; Molina JM; Bouchaud O; Katlama C; Costagliola D;
    J Antimicrob Chemother; 2008 Oct; 62(4):797-808. PubMed ID: 18641035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.
    Waters L; Bansi L; Asboe D; Pozniak A; Smit E; Orkin C; Fearnhill E; Dunn D; Phillips A; ;
    Antivir Ther; 2013; 18(2):213-9. PubMed ID: 23653911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
    Álvarez H; Rava M; Martínez C; Portilla J; Peraire J; Rivero A; Cervero M; Mariño A; Poveda E; Llibre JM;
    HIV Med; 2022 Sep; 23(8):825-836. PubMed ID: 35234328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comorbidity and polypharmacy among women living with HIV in British Columbia.
    Donaldson MA; Campbell AR; Albert AY; Borhani M; Nesbitt A; Côté HCF; Maan EJ; Pick N; Murray MCM;
    AIDS; 2019 Dec; 33(15):2317-2326. PubMed ID: 31764097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.